Zacks: Analysts Expect Spero Therapeutics Inc (SPRO) Will Announce Quarterly Sales of $400,000.00

Brokerages predict that Spero Therapeutics Inc (NASDAQ:SPRO) will report $400,000.00 in sales for the current quarter, according to Zacks. Two analysts have made estimates for Spero Therapeutics’ earnings, with the highest sales estimate coming in at $600,000.00 and the lowest estimate coming in at $200,000.00. The firm is expected to issue its next quarterly earnings report on Thursday, March 8th.

According to Zacks, analysts expect that Spero Therapeutics will report full year sales of $400,000.00 for the current fiscal year, with estimates ranging from $1.19 million to $1.58 million. For the next year, analysts anticipate that the company will report sales of $8.20 million per share. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.20 million.

A number of equities research analysts have recently issued reports on the stock. Oppenheimer set a $30.00 price target on shares of Spero Therapeutics and gave the stock a “buy” rating in a report on Thursday, January 11th. Bank of America started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating on the stock. Stifel Nicolaus started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Cowen started coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating on the stock.

Shares of Spero Therapeutics (NASDAQ SPRO) traded up $0.47 during trading on Friday, hitting $12.06. 36,186 shares of the stock were exchanged, compared to its average volume of 31,336. Spero Therapeutics has a 52-week low of $9.84 and a 52-week high of $15.40.

In related news, Director Casper Breum bought 214,285 shares of the stock in a transaction that occurred on Monday, November 6th. The shares were acquired at an average cost of $14.00 per share, with a total value of $2,999,990.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Plc Glaxosmithkline bought 428,571 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The disclosure for this purchase can be found here. Insiders purchased 649,356 shares of company stock worth $9,090,984 over the last ninety days. 13.90% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/20/zacks-analysts-expect-spero-therapeutics-inc-spro-will-announce-quarterly-sales-of-400000-00.html.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply